About inovio pharmaceuticals - INO
Inovio Pharmaceuticals, Inc. engages in the provision of designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with human papillomavirus. Its product pipeline includes VGX-3100, INO-3107, INO-5410, INO-4800, and PENNVAX-GP. The company was founded by David B. Weiner on June 29, 1983 and is headquartered in Plymouth Meeting, PA.
INO At a Glance
Inovio Pharmaceuticals, Inc.
660 West Germantown Pike
Plymouth Meeting, Pennsylvania 19462-1111
| Phone | 1-267-440-4200 | Revenue | 65.34K | |
| Industry | Pharmaceuticals: Major | Net Income | -84,945,901.00 | |
| Sector | Health Technology | Employees | 112 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
INO Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 1,248.525 |
| Price to Book Ratio | 4.982 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -0.387 |
| Enterprise Value to Sales | 496.422 |
| Total Debt to Enterprise Value | 0.289 |
INO Efficiency
| Revenue/Employee | 583.42 |
| Income Per Employee | -758,445.545 |
| Receivables Turnover | 145.207 |
| Total Asset Turnover | 0.001 |
INO Liquidity
| Current Ratio | 1.40 |
| Quick Ratio | 1.40 |
| Cash Ratio | 1.34 |
INO Profitability
| Gross Margin | -4,474.063 |
| Operating Margin | -132,871.31 |
| Pretax Margin | -130,000.002 |
| Net Margin | -130,000.002 |
| Return on Assets | -89.142 |
| Return on Equity | -183.468 |
| Return on Total Capital | -253.842 |
| Return on Invested Capital | -156.563 |
INO Capital Structure
| Total Debt to Total Equity | 38.877 |
| Total Debt to Total Capital | 27.994 |
| Total Debt to Total Assets | 12.378 |
| Long-Term Debt to Equity | 27.163 |
| Long-Term Debt to Total Capital | 19.559 |